Medicare Beneficiaries In Observation Care May Face Surprise Hospital, Nursing Home Bills
A Modesto Bee article examines the costs for one woman. Also, KHN reports on problems with a Medicare program designed to help poorly performing nursing homes.
The independent source for health policy research, polling, and news.
32,541 - 32,560 of 112,425 Results
A Modesto Bee article examines the costs for one woman. Also, KHN reports on problems with a Medicare program designed to help poorly performing nursing homes.
The Association for Accessible Medicines is suing the state, saying the legislation grants Maryland power to regulate sales outside its borders.
The therapy known as CAR-T can’t be stockpiled. “God, it’s awful,’’ said Carl June from the University of Pennsylvania. “I can’t tell you how bad.’’ In other pharmaceutical news, rare-disease drugmakers speak out against the Republican health care bill, a study finds that risks for drugs are not prominent and accessible on smartphones, and a conservative group pushes for House Energy and Commerce Chairman Greg Walden's support on right-to-try legislation.
Dr. Brenda Fitzgerald may prove to be a controversial pick. In 2014 during the West African Ebola crisis, Georgia Gov. Nathan Deal stated that water destroys Ebola viruses and attributed the false notion to Fitzgerald.
The insurer says the state owes it nearly $700 million but it hopes an accommodation can be reached.
The premium hikes for the company's policies will range from more than 25 percent to 55.7 percent. Blue Cross is the only insurer in 96 of Georgia’s 159 counties.
The steps states are taking to change the program could affect millions of people. In other news, the Los Angeles Times offers a detailed look at how much counties that went for Trump rely on Medicaid and CHIP.
Republicans are finding out they need to keep a lot of the provisions from the Affordable Care Act. Meanwhile, some senators say they may be weeks away from a vote.
Former rivals, President Donald Trump and Sen. Rand Paul (R-Ky.), are presenting a somewhat unified front on health care efforts that don't always align with the stance of Republican leaders on Capitol Hill.
Sen. Ted Cruz's name used to be synonymous with firebrand tactics to disrupt the health law. Now his fellow Republican senators are more likely to describe him as a constructive compromiser. That doesn't mean he's not facing heat with his constituents, though.
On Thursday night, Sen. Jerry Moran (R-Kan.) did what many Republicans have avoided this recess: face head on his constituents' tough questions on health care. The concerns he heard are ones that echo across the country, and demonstrate how hard it will be to get the legislation passed.
Senate Majority Leader Mitch McConnell says he will have a new bill ready for the returning lawmakers, but that if they can't reach an agreement "no action is not an alternative" that's acceptable.
Today's early morning highlights from the major news organizations.
A selection of opinions on the health care debate from around the country.
Each week, KHN's Shefali Luthra finds interesting reads from around the Web.
Media outlets report on news from Wisconsin, Oregon, West Virginia, Illinois, Connecticut, Louisiana, Texas, Minnesota, New Hampshire and Maryland.
NantWorks, a company controlled by Dr. Patrick Soon-Shiong, will acquire a majority stake in Integrity Healthcare, which operates the hospital chain Verity Health. And, development at other hospitals in California, Maryland, Missouri, Texas and Minnesota also make the news.
Other public health news stories today report on developments related to the organ donation shortage, a link between sleep quality and Alzheimer's, sugar consumption during pregnancy, gene cloning, ALS, heat stroke and the role of the sense of smell on weight.
They credit Indiana's state health commissioner and surgeon general nominee Jerome Adams for making life-saving strides against the epidemic in his state. Meanwhile, the drug crisis is taking its toll on medical examiner offices.
Also in pharmaceutical news: the debilitating cost of hepatitis C drugs, clinical trials for blood cancer treatment, investments into fighting our biggest killers and scrutiny for prescription drug ads.
© 2026 KFF